Screener
Theravance Biopharma TBPH Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $219.77M-22.0% | $288.1M+160% | $167.81M+344% | $174.77M+648% | $281.93M+508% | ||
| $167.89M+195% | $106.57M+426% | $147.55M+192% | $154.91M+128% | $56.88M+14.4% | ||
| $416.66M+13.8% | $417.63M+178% | $418.46M+160% | $354.7M+205% | $366.29M+207% | ||
| $5.17M-22.2% | $5.54M-21.2% | $5.9M-20.5% | $6.26M-19.7% | $6.64M-18.4% | ||
| $469.77M+10.3% | $472.31M+37.5% | $485.57M+37.1% | $415.46M+16.7% | $426.04M+17.7% | ||
| $652K-61.1% | $1.1M-54.3% | $2.57M+14.5% | $2.21M+52.2% | $1.68M+0.1% | ||
| $30.77M-43.7% | $31.78M+0.9% | $38.3M+19.4% | $37.41M+59.6% | $54.63M+138% | ||
| $1K0.0% | $1K0.0% | $1K— | $1K— | $1K— | ||
| -$870.46M+5.8% | -$864.56M+11.7% | -$859.63M+11.0% | -$920.65M+3.1% | -$924.27M+1.4% | ||
| $289.71M+28.8% | $290.59M+75.1% | $296.72M+69.0% | $232.68M+25.3% | $224.85M+16.1% | ||
| $469.77M+10.3% | $472.31M+37.5% | $485.57M+37.1% | $415.46M+16.7% | $426.04M+17.7% |
FAQ
- What are Theravance Biopharma's total assets?
- Theravance Biopharma (TBPH) holds $469.8M in total assets, up 10.3% year over year.
- How much debt does Theravance Biopharma have?
- Theravance Biopharma carries $38.6M in total debt against $289.7M of shareholders' equity, a debt-to-equity ratio of 0.13.
- How much cash does Theravance Biopharma have?
- Theravance Biopharma holds $219.8M in cash and equivalents.
- Can Theravance Biopharma cover its short-term obligations?
- Its current ratio is 13.54 — current assets exceed current liabilities.
- Where does Theravance Biopharma's balance sheet data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
